In China’s ICU supply chain, a ventilator that merges turbine independence with high-flow therapy

Crius V6 ICU Ventilator – Advanced Mechanical Ventilation with HFNC & Turbine Technology

Hospitals managing acute respiratory failure have long faced a logistical compromise: choose a dedicated high-flow nasal cannula (HFNC) system and a separate ICU ventilator, or accept a machine that does neither particularly well. The Crius V6 sidesteps that trade-off by integrating invasive, non-invasive, and high-flow oxygen delivery into a single, turbine-driven platform. For a Chinese manufacturer, that design choice reflects a broader shift in how critical care equipment is being rationalized for cost-sensitive health systems.

The ventilator’s most consequential engineering detail is its turbine—no external compressor or central gas pipeline is required. This unhooks the device from fixed infrastructure, making it functional in ICUs, operating rooms, and during in-hospital transport. The turbine also enables fast triggering and reduced inspiratory delay, which matters for patients who are breathing spontaneously and need the machine to respond quickly rather than override their own effort.

Clinically, the V6 covers the standard ventilation modes—VCV, PCV, PRVC, SIMV, CPAP/PSV, APRV, and Dual PAP—plus optional AMV and nCPAP. Its tidal volume range of 20 to 2000 mL accommodates both adult and pediatric cases, though the inclusion of pediatric support stops short of full neonatal capability. The HFNC function delivers oxygen flows up to 100 L/min, which places it in the upper tier of non-invasive respiratory support for severe hypoxemia.

On the monitoring side, the V6 provides lung compliance measurement, RSBI, P0.1 occlusion pressure, expiratory hold maneuvers, and multi-loop graphics. These are not merely add-ons; they allow clinicians to assess patient readiness for extubation and adjust support levels in real time. In an ICU where staffing is stretched, having that data on a single screen reduces the feedback loop between bedside nurse and respiratory therapist.

China’s ventilator manufacturing ecosystem has matured rapidly since the COVID-19 pandemic exposed global supply chain vulnerabilities. The Crius V6 is a product of that maturation: it uses a domestic turbine supply chain, avoids reliance on precision pneumatics from European suppliers, and bundles features that previously required multiple vendor contracts. For tier-2 city hospitals in China, where central gas infrastructure is less reliable, the turbine independence is a practical advantage, not just a spec sheet line item.

The machine does not target the premium segment occupied by brands like Hamilton or Dräger. Instead, it positions itself in the value-driven tier of the market—adequate for most ICU cases, robust enough for transport, and versatile enough to replace two pieces of equipment with one. That kind of product logic gains traction in health systems where procurement decisions are judged by both clinical outcome and capital efficiency.

What the V6 reveals is how far the Chinese medical equipment industry has moved from component assembly toward system-level product thinking. The integration of HFNC into a turbine ventilator is not a technical novelty—it is a response to real-world constraints on space, training, and procurement budgets. Those constraints, not algorithms, are shaping the next generation of critical care hardware.

Why it matters:
For hospital groups looking to standardize respiratory support across multiple ICUs, the Crius V6 offers a single SKU that covers the majority of adult and pediatric ventilation needs. Its turbine-based design cuts infrastructure costs, and its combined HFNC/ventilator capability reduces device inventory. In markets where procurement specificity is tightening, this kind of consolidation has real purchasing appeal.

View Product →